Form 4: Integra LifeSciences Holdings Corp: Executive Vice President Reports Stock Transactions

Robert T. Davis Jr., EVP & President, TT, of Integra LifeSciences Holdings Corp, reports acquisition and disposal of common stock and stock options.

Summary

• Robert T. Davis Jr., an Executive Vice President at Integra LifeSciences Holdings Corp, filed a Form 4 detailing changes in beneficial ownership.
• On March 11, 2025, Davis disposed of 472 shares of common stock at $23.95 and another 907 shares at $23.95.
• Also on March 11, 2025, Davis acquired 12,425 shares of common stock at $0.
• Following these transactions, Davis directly owns 75,561 shares of common stock.
• Davis also acquired 26,310 non-qualified stock options with an exercise price of $23.95, exercisable in installments starting March 11, 2025, and expiring on March 11, 2033.
• Davis directly owns 26,310 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there were disposals of shares, the acquisition of a larger number of shares and stock options suggests a continued positive outlook by the executive.

Positives

• The acquisition of 12,425 shares at $0 increases Davis's direct ownership in the company.
• The grant of 26,310 stock options aligns Davis's interests with the long-term performance of the company.

Negatives

• The disposal of 472 and 907 shares could be interpreted negatively, although the acquisition of a larger number of shares offsets this.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are routinely disclosed to the SEC. These transactions can be influenced by various factors, including personal financial planning, company performance, and executive compensation plans.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the medical device industry to incentivize performance and align executive interests with shareholder value.
• Companies like Stryker, Medtronic, and Boston Scientific also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 25% annually over four years is a standard practice for stock option grants.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates